See also separate entry for sofosbuvir.
- TRADE NAME: Epclusa (Gilead)
- INDICATIONS: Hepatitis C
- CLASS: Direct-acting antiviral, Hepatitis C virus NS5A inhibitor (velpatasvir), Hepatitis C virus nucleotide analog NS5B polymerase inhibitor (sofosbuvir)
- HALF-LIFE: <27 hours (sofosbuvir); 15 hours (velpatasvir)
- FDA APPROVAL DATE: 06/28/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Carbamazepine, Doravirine/Lamiduvine/Tenofovir Disoproxil, Efavirenz, Omeprazole, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort, Topotecan - PREGNANCY: Insufficient evidence to inform drug-associated risk; contra-indicated in pregnancy when given with ribavirin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 06/10/2025
